Conditions: Anemia Kidney Failure, Chronic
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 152
Healthy volunteers: no

Brief summary:
To assess the incidence rate of Treatment Emergent Adverse Events (TEAEs) over 2 years in patients treated with Dynepo.

Detailed description:

Arms:
arm 1: Subjects received Dynepo (Epoetin delta) either twice weekly (BIW), once weekly (QW), once every 2 weeks (Q2W) or once every 4 weeks (Q4W) based on what is appropriate for the subject

Interventions: intervention 1: Dynepo
Intervention descriptions: intervention 1: Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject

Protocol document: